​

Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

DNTH Stock Forecast

Dianthus Therapeutics (DNTH) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $115.00, with a high of $145.00 and a low of $55.00. This represents a 50.43% increase from the last price of $76.45.

- $30 $60 $90 $120 $150 High: $145 Avg: $115 Low: $55 Last Closed Price: $76.45

DNTH Stock Rating

Dianthus Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 9 Buy (90.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 9 1 Strong Sell Sell Hold Buy Strong Buy

DNTH Price Target Upside V Benchmarks

TypeNameUpside
StockDianthus Therapeutics50.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1418
Avg Price Target$132.00$118.75$101.11
Last Closing Price$76.45$76.45$76.45
Upside/Downside72.66%55.33%32.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-15---15
May, 26-16---16
Apr, 26-15---15
Mar, 26113---14
Feb, 26113---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2026Jefferies$132.00$76.4272.73%72.66%
May 11, 2026Gavin Clark-GartnerEvercore ISI$120.00$88.4535.67%56.97%
May 06, 2026Raymond James$125.00$87.8342.32%63.51%
Apr 08, 2026Andy ChenWolfe Research$98.00$87.4812.03%28.19%
Mar 09, 2026Maury RaycroftUBS$98.00$79.2323.69%28.19%
Mar 09, 2026Maury RaycroftJefferies$98.00$79.2323.69%28.19%
Mar 09, 2026Trevor AllredOppenheimer$145.00$80.8879.28%89.67%
Mar 09, 2026Alex ThompsonStifel Nicolaus$120.00$80.6048.88%56.97%
Feb 11, 2026Wedbush$55.00$49.7010.66%-28.06%
Jan 29, 2026UBS$125.00$53.23134.83%63.51%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026GuggenheimBuyBuyhold
Jun 10, 2026JefferiesBuyBuyhold
Jun 10, 2026Cowen & Co.BuyBuyhold
Jun 10, 2026Raymond JamesStrong BuyStrong Buyhold
Jun 10, 2026Wolfe ResearchOutperformOutperformhold
May 11, 2026Evercore ISIOutperformOutperformhold
May 06, 2026Raymond JamesStrong BuyStrong Buyhold
Apr 08, 2026Wolfe ResearchOutperforminitialise
Mar 16, 2026William BlairOutperformOutperformhold
Mar 10, 2026Raymond JamesOutperformStrong Buyupgrade

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.45$-2.55----
Avg Forecast$-5.53$-2.56$-3.45$-3.94$-4.16$-3.87
High Forecast$-3.77$-2.10$-2.59$-2.80$-2.62$-2.30
Low Forecast$-7.29$-3.00$-4.58$-5.25$-6.71$-6.35
Surprise %52.80%-0.39%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.83M$6.24M$2.04M---
Avg Forecast$2.46M$5.54M$3.71M$4.11M$19.11M$75.36M
High Forecast$2.65M$6.72M$5.54M$6.13M$28.53M$112.53M
Low Forecast$2.12M$4.65M$2.55M$2.82M$13.13M$51.80M
Surprise %14.80%12.46%-45.13%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.55M$-84.97M$-162.34M---
Avg Forecast$-28.50M$-13.15M$-18.47M$-20.76M$-24.05M$-19.93M
High Forecast$-19.43M$-10.82M$-13.35M$-14.45M$-13.52M$-11.83M
Low Forecast$-37.57M$-15.48M$-23.59M$-27.08M$-34.57M$-32.70M
Surprise %52.83%546.21%778.77%---

DNTH Forecast FAQ

Is Dianthus Therapeutics stock a buy?

Dianthus Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Dianthus Therapeutics is a favorable investment for most analysts.

What is Dianthus Therapeutics's price target?

Dianthus Therapeutics's price target, set by 10 Wall Street analysts, averages $115 over the next 12 months. The price target range spans from $55 at the low end to $145 at the high end, suggesting a potential 50.43% change from the previous closing price of $76.45.

How does Dianthus Therapeutics stock forecast compare to its benchmarks?

Dianthus Therapeutics's stock forecast shows a 50.43% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Dianthus Therapeutics over the past three months?

  • June 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Dianthus Therapeutics’s EPS forecast?

Dianthus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.94, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-4.16 in 2027, and $-3.87 in 2028.

What is Dianthus Therapeutics’s revenue forecast?

Dianthus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $4.11M, reflecting a 101.71% increase from the reported $2.04M in 2025. The forecast for 2027 is $19.11M, and $75.36M for 2028.

What is Dianthus Therapeutics’s net income forecast?

Dianthus Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-20.762M, representing a -87.21% decrease from the reported $-162M in 2025. Projections indicate $-24.045M in 2027, and $-19.929M in 2028.